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Somatic mutations of LKB1 tumour suppressor gene have been detected in human cancers including non-small cell lung cancer
(NSCLC). The relationship between LKB1 mutations and clinicopathological characteristics and other common oncogene mutations
in NSCLC is inadequately described. In this study we evaluated tumour specimens from 310 patients with NSCLC including those
with adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma histologies. Tumours were obtained from patients
of US (n¼143) and Korean (n¼167) origin and screened for LKB1, KRAS, BRAF, and EGFR mutations using RT—PCR-based
SURVEYOR-WAVE method followed by Sanger sequencing. We detected mutations in the LKB1 gene in 34 tumours (11%). LKB1
mutation frequency was higher in NSCLC tumours of US origin (17%) compared with 5% in NSCLCs of Korean origin (P¼0.001).
They tended to occur more commonly in adenocarcinomas (13%) than in squamous cell carcinomas (5%) (P¼0.066). LKB1
mutations associated with smoking history (P¼0.007) and KRAS mutations (P¼0.042) were almost mutually exclusive with EGFR
mutations (P¼0.002). The outcome of stages I and II NSCLC patients treated with surgery alone did not significantly differ based on
LKB1 mutation status. Our study provides clinical and molecular characteristics of NSCLC, which harbour LKB1 mutations.
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Peutz–Jeghers syndrome (PJS) is caused by mutations in the LKB1
tumour suppressor gene (Hemminki et al, 1998). LKB1 is serine–
threonine kinase, which has been shown to regulate cell cycle
progression, apoptosis, and cell polarity (Tiainen et al, 1999). The
major target of LKB1 kinase activity is thought to be
AMP-activated protein kinase (AMPK). AMPK is activated under
low cellular energy conditions by raising AMP levels and it
phosphorylates multiple downstream targets including tubero-
sclerosis complex 2 gene, which represses mTOR signalling.
Phosphorylation of AMPK by LKB1 is needed for full activity of
AMPK and suppression of mTOR activity under low energy
conditions (Shaw et al, 2004). The hallmarks of PJS include
mucocutaneous pigmentation and hamartomatous polyps of the
gastrointestinal tract. Patients with PJS have an increased risk of
developing gastrointestinal, pancreatic, breast, gynecological, and
non-small cell lung cancers (NSCLC). The overall risk for cancers
is increased 5- to 12-fold in different age groups compared with the
general population (Hearle et al, 2006). Somatic mutations of the
LKB1 tumour suppressor have rarely been found in cancers from
patients who do not have PJS except for NSCLC (Avizienyte et al,
1999). Previous reports have suggested the LKB1 mutation rate to
be as high as 30% in NSCLC tumours and cell lines derived from
patients of Caucasian origin (Carretero et al, 2004; Matsumoto
et al, 2007) and to be infrequent in NSCLC patients of Asian origin
(3%) (Onozato et al, 2007). Furthermore, LKB1 mutations have
been shown to be associated with adenocarcinoma histology, male
gender, and smoking history (Matsumoto et al, 2007). A recent
report of using a mouse model for lkb1 inactivation in NSCLC has
provided insights into the role of the gene in this cancer. This
study showed that lkb1 inactivation in combination with activating
mutations of kras using inducible promoters in the lung was
associated with decreased survival compared with kras mutation
alone (Ji et al, 2007).
Current screening techniques for LKB1 tumour suppressor
mutations rely on conventional exonic sequencing of the DNA,
which can identify single base pair changes and small deletions/
insertions (Ballhausen and Gunther, 2003). The addition of
multiple ligation-dependent probe amplification (MLPA), which
enables detection of exonic and whole gene deletions, with exonic
sequencing has increased the mutation detection rates to 80% in
patients with PJS phenotype (Volikos et al, 2006). Conventional Revised 9 May 2008; accepted 28 May 2008; published online 1 July 2008
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ssequencing has also been used to detect mutations of LKB1 at
mRNA level and some mutations missed by sequencing at the DNA
level have been discovered by mRNA-based approaches (Abed
et al, 2001). However, mutant forms of LKB1 mRNAs can have a
shortened half-life because of nonsense-mediated decay, which can
potentially interfere with mutation detection (Abed et al, 2001).
We have recently described a rapid and sensitive enzymatic
method to detect mutations in epidermal growth factor (EGFR)o f
DNA from fresh tissue and paraffin-embedded tissues (Janne et al,
2006). This method includes amplification of region of interest
with PCR, SURVEYOR endonuclease digestion of the products,
which cleaves mismatched heteroduplex DNAs, and detection of
DNA fragments by sensitive high-performance liquid chromato-
graphy (HPLC) WAVE HS system. Subsequently, SURVEYOR-
positive specimens are fractionated in partially denaturing
conditions and are Sanger-sequenced. The major advantages of
SURVEYOR-WAVE method are the fast exclusion of wild-type
specimens without laborious conventional sequencing and high
sensitivity. The SURVEYOR-WAVE method is more sensitive than
conventional sequencing as it can detect mutant DNA sequences
when they are present in 1% or more of total DNA (Janne et al,
2006).
The current study was designed to analyse the incidence of LKB1
mutations in NSCLC. Furthermore, we wanted to investigate the
LKB1 mutational frequency in different histologies and ethnic
backgrounds, and assess their correlation to smoking history,
gender, stage, survival, and other oncogenic mutations in NSCLC.
MATERIALS AND METHODS
Cell lines and tumour specimens
The NSCLC cell lines A549, NCI-H1395, NCI-H1650, NCI-H1666,
NCI-H1781, NCI-1975, NCI-H23, NCI-H2126, NCI-H441, NCI-
H820, HCC2935, HCC4006, and HCC827 were purchased from
ATCC (Manassas, VA, USA). H3255, H3255GR, HCC2279, and
PC-9 have been previously described (Ono et al, 2004; Tracy et al,
2004; Engelman et al, 2006). Ma1, and Ma70 are NSCLC cell lines
harbouring EGFR mutations that were established at the Kinki
University, Osaka, Japan. A549, NCI-H1395, NCI-H1666, NCI-H23,
NCI-H2122, NCI-H2126, and NCI-H460 have previously been
reported to contain LKB1 mutations (Sanchez-Cespedes et al, 2002;
Bamford et al, 2004; Carretero et al, 2004).
NSCLC tumours (n¼310) were collected from surgical resec-
tions from patients with stages I–IV NSCLC when sufficient
material for RNA extraction was available. The majority of the
specimens (n¼167) was collected at the Samsung Medical Center,
Seoul, Korea. Frozen tumour tissues were collected from 809 out of
2442 patients who underwent curative resection for NSCLC from
November 1995 to February 2007 at Samsung Medical Center. One
or two pieces from the periphery of the tumour masses – avoiding
necrotic regions – were immediately frozen at –801C until
retrieved. Medical records and haematoxylin and eosin-stained
slides of the specimen were reviewed by a single pathologist. Only
frozen tumour tissues from adenocarcinoma or squamous cell
carcinoma (according to the 2004 World Health Organization
histopathological criteria) were included. Only frozen tumour
tissues with a tumour cell content of more than 70% were used for
further analysis. In addition, frozen tumour tissues of the following
patients were excluded from the study: patients who had received
preoperative neoadjuvant treatments, patients with double pri-
mary lung cancer, and patients who had undergone incomplete
resections or who had not been subjected to mediastinal lymph
node dissections. Selected frozen tumour tissues were used for the
microdissection. Briefly, frozen tissues were lightly stained with
haematoxylin–eosin to improve visualisation, and necrotic
tumour tissues and intervening normal tissues were removed.
Each of the microdissected tumour tissues with a tumour cell
content of more than 90% was placed in 1ml Easy Blue reagent of a
commercially available RNA isolation kit (easy-spint Total RNA
Extraction Kit, iNtRON Biotechnology, Gyeonggi-do, Korea),
immediately homogenised by vortexing, and the total RNA was
extracted. The quantity and quality of RNA were analysed using a
spectrometer (Nanodrop Technologies, Rockland, DE, USA) and
Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit, Agilent
Technologies Inc., Bo ¨blingen, Germany), respectively. Finally, 167
frozen tissues with acceptable quality of RNA (RNA Integrity
Number (RIN) value over 7.0) were used for the current studies.
All patients provided written informed consent.
The tumours from Caucasian patients (n¼143) were collected
at the Brigham and Women’s Hospital, Boston, MA, USA between
1991 and 1997 and have been previously published for patient
characteristics and histology, and for expression profile-based
clustering of the tumours (Bhattacharjee et al, 2001; Hayes et al,
2006). Frozen samples of resected lung tumours were obtained
within 30min of resection and subdivided into 100mg samples
and snap frozen at  801C. Each specimen was associated with an
immediately adjacent sample embedded for histology in an
optimal cutting temperature medium and stored at  801C. Six
micrometres of frozen sections of embedded samples stained with
haematoxylin and eosin were used to confirm the postoperative
pathological diagnosis and to estimate the cellular composition of
adjacent samples. All specimens underwent pathological review by
two pathologists. In all 109 tumours obtained during the same time
period were excluded because they did not meet one or more of the
eligibility criteria. Tissue samples were homogenised in Trizol (Life
Technologies, Gaithersburg, MD, USA) and RNA was extracted
and purified by using the RNeasy column purification kit (Qiagen,
Chatsworth, CA, USA). Denaturing formaldehyde gel electrophor-
esis followed by northern blotting using a b-actin probe assessed
RNA integrity. Samples were excluded if b-actin was not full
length. All patients provided written informed consent. The US
cohort included specimens that have previously undergone
analyses and the results have been published for EGFR, KRAS,
and BRAF mutations (Bhattacharjee et al, 2001; Naoki et al, 2002;
Hayes et al, 2006). We reconfirmed the mutations in 30 of these
specimens using the SURVEYOR-based analysis (see section
SURVEYOR digestion and HPLC analysis) and found 100%
concordance between the two methods (data not shown).
Cell line specimens were snap frozen and stored at –801C. RNA
was extracted from tumours and cell lines using Trizol (Invitrogen,
Carlsbad, CA, USA), purified with Rneasy Mini Kit (Qiagen,
Valencia, CA, USA) and was used for cDNA synthesis using the
QuantiTect reverse transcription kit (Qiagen, Valencia, CA, USA).
PCR primers and cycling conditions
For LKB1 gene analysis, PCR primers were designed to amplify the
cDNA in two amplicons. PCR primers of the first amplicon were
designed to hybridise to the noncoding area of the mRNA
upstream of exon 1 (50-agggaagtcggaacacaagg-30) and to exon 5
(50-ccagatgtccaccttgaagc-30) generating a PCR product of 797bp.
The primers for the second amplicon located at exon 5 (50-aacggcc
tggacaccttct-30) and to noncoding exon 10 (50-gaaccggcaggaagact
gag-30) generating a product of 702bp, which has an overlapping
part with first amplicon. For SURVEYOR-WAVE analysis of KRAS,
PCR primers (50-ggcctgctgaaaatgactga-30,5 0-tcctgagcctgttttgtgtct-
30) were designed to generate an amplicon of 407bp covering
codons 12, 13 and 61, which are the codons commonly mutated in
lung cancers. For SURVEYOR-WAVE mutation analysis of BRAF,
cDNA was amplified in two overlapping amplicons (50-aggattt
cgtggtgatggag-30,5 0-gatgacttctggtgccatcc-30, and 50-gacgggactcgagt
gatgat-30,5 0-ggtatcctcgtcccaccata-30) covering codons 387–673.
For SURVEYOR-WAVE analysis of EGFR, PCR amplification
was done in a single amplicon (50-ggagcctcttacacccagtg-30,
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s50-aggtcatcaactcccaaacg-30), which covered exons 18–21 of the
gene. PCR amplification was done using JumpStart Taq (Sigma, St
Louis, MO, USA) under the manufacturer’s guidelines. A part of
the specimens (n¼103) was previously characterised for KRAS,
BRAF, EGFR mutations using reverse transcritase (RT)–PCR and
direct sequencing of the PCR products (Naoki et al, 2002; Hayes
et al, 2006).
SURVEYOR digestion and HPLC analysis
SURVEYOR digestion and HPLC analysis were carried out as
described previously (Janne et al, 2006). In brief, PCR products
were digested in reaction mixture containing equal volumes of
SURVEYOR enzyme (Transgenomics, Omaha, NE, USA) and
Enhancer (Transgenomics, Omaha, NE, USA) at 421C for 20min
followed by termination of the reaction by Stop Solution
(Transgenomics, Omaha, NE, USA). Specimens were then loaded
to the WAVE HS HPLC (Transgenomics, Omaha, NE, USA) at
501C, eluted with an increasing acetonitrile gradient, and detected
by UV detector using DNA intercalating fluorescence dye
(Transgenomics, Omaha, NE, USA). When cell lines known to be
homozygous for specific mutation were analysed, PCR products
were mixed 1:1 with PCR products of a wild-type cell line,
denatured by heating, and slowly renatured to generate hetero-
duplexes.
Sequencing and fractionation
Specimens that showed an altered pattern on the SURVEYOR
tracings were purified using QIAquick kit (Qiagen, Valencia, CA,
USA) and sequenced bi-directionally by molecular biology core
facility of Dana–Farber Cancer Institute. If a specimen showed an
altered pattern on the SURVEYOR tracing but had a wild-type
sequence by direct DNA sequencing, it underwent fractionation by
WAVE HS HPLC in partially denaturing conditions. Running
temperatures for specific amplicons were calculated by the
Navigator Software (Transgenomics, Omaha, NE, USA). Collected
fragments were amplified with PCR using the same primers as in
the original amplification, purified and sequenced as previously
described above.
Statistical analysis
Fisher’s exact test was used to assess the association of LKB1
mutation status with other clinical, pathological, and genetic
characteristics. To adjust for any difference between ethnic groups,
the association between LKB1 mutation rate and each character-
istic was also evaluated as stratified contingency tables. If we did
not reject that the odds ratios were the same across ethnic groups,
we then tested whether the common odds ratios were unity based
on the stratified Mantel–Haenszel estimate (Breslow and Day,
1980). Overall survival was estimated using the Kaplan–Meier
method, with differences between the groups compared using the
log-rank test. All P-values were based on a two-sided hypothesis,
with Po0.05 considered to be statistically significant and
0.05oPo0.10 considered to be borderline significant.
RESULTS
SURVEYOR-WAVE mutation detection of LKB1 tumour
suppressor in NSCLC cell lines
The impact of the stability of LKB1 mRNA on detecting LKB1
mutations was tested using RT–PCR with mRNA extracted from
NSCLC cell lines that had previously been characterised for LKB1
mutations. These included NCI-H441 (wild type) and A549, NCI-
H1395, NCI-H23, and NCI-H2126 (all containing LKB1 mutations).
Reverse transcriptase–PCR amplification of the whole coding
region of the LKB1 mRNA showed that cell lines with nonsense
(A549, NCI-H23) mutations or 1bp deletion (H1395) expressed
mRNA with comparable size to the wild-type H441 cell line
(1460bp). H2126 cell line, which is known to have homozygous
deletion of exons 4–6, expressed mRNA with substantially smaller
size (B1000bp) corresponding to deletion of 398bp. RT–PCR
revealed no major difference in LKB1 mRNA expression levels
between LKB1 mutant or wild-type cell lines (Figure 1A).
As LKB1 mutant and wild-type cell lines expressed comparable
amounts of LKB1 mRNA with RT–PCR, we studied the cDNA for
mutations using the SURVEYOR-WAVE method. The WAVE
HPLC provides a system to analyse DNA fragments smaller than
900bp and therefore we designed two overlapping amplicons
covering exons 1–5 (797bp) and 5–9 (702bp) to amplify the
whole coding region of LKB1 mRNA. PCR products of LKB1
mutant cell lines were mixed 1:1 with the products from wild-type
cell lines (H441) to generate heteroduplexes as LKB1 mutant cell
lines were previously reported to be homozygous for the
inactivation of the gene. SURVEYOR-WAVE analysis of the
amplicon covering exons 1–5 revealed novel peaks with the cDNA
for A549, and NCI-H1395 cell lines compared with the wild type
from NCI-H441 (Figure 1B). SURVEYOR-WAVE analysis of exons
5–9 showed novel peaks for the NCI-H23 cell line as well. The
mutations detected with SURVEOR-WAVE were confirmed by
conventional DNA sequencing and they corresponded to previous
reports (Sanchez-Cespedes et al, 2002; Carretero et al, 2004). We
could not detect the LKB1 mutation of H2126 cell line with
SURVEYOR-WAVE method using a two-amplicon approach
because this cell line has a homozygous deletion of exons 4–6
and the reverse primer of the first amplicon and the forward
primer of the second amplicon, which lie on the deleted part of the
gene (data not shown).
LKB1 tumour suppressor gene mutations in NSCLC
tumours
We next used the SURVEYOR-WAVE method to screen NSCLC
tumour specimens (n¼310) for LKB1 mutations. We detected 34
LKB1 mutations (11%) in the NSCLC tumour specimens (Table 1).
The majority of the LKB1 mutations detected was deletions or
insertions (n¼25, 74%). The remainder was missense (n¼7, 21%)
and nonsense (n¼2, 6%) mutations (Table 2, Figure 1C). About
one-half of the deletions and insertions were small, covering
o15bp (n¼14, 56%), whereas larger deletions (n¼11, 44%)
covering hundreds of base pairs were detected in the remaining
specimens. Some mutational hotspots were discovered. The areas
that had the same mutation in more than one tumour specimen
included deletion of exon 4 (n¼4), deletion of exons 2 and 3
(n¼3), D194Y (n¼2), and P281L (n¼2). Interestingly, a
significant portion of the mutations was located in exon 1
(n¼11, 32%) but there was no area of recurrent mutations in
this exon (Table 2). Of the missense mutations detected in the
current study, all except R426W are in the kinase domain of the
protein. Missense mutations in codons 176 and 194 have been
previously characterised in PJS (Launonen, 2005). We also found
four F354L alterations (data not shown) but we did not consider
these as missense mutations as this alteration has previously been
reported to be a rare polymorphism of the gene (Launonen et al,
2000). We did not have access to the corresponding normal tissues
and therefore, we could not verify if some of the missense
mutations were somatic or germline.
Association of LKB1 tumour suppressor mutations in
NSCLC with clinicopathological characteristics
The mutation frequency of LKB1 gene was significantly higher in
NSCLCs in the Caucasian cohort (Table 1). Twenty-five (17% of
specimens) of the LKB1 mutations were detected in NSCLCs
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H2126
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H441 H1395
H441 H441
H441
H441
H23
A549
AD368
142_143delA, FS truncation 165_169delG, FS truncation
996G>A, W332X
AD362
AD362
ex6del, FS truncation
AD367
AD368
475C>T, Q159X 109C>T, Q37X
H1395 + H441
H123 + H441
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* *
*
*
*
*
* * * *
*
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1.0
1.2
1.5
kbp
wt A
BC
LKB1 mutant
A549 + H441
Figure 1 Mutation analysis of LKB1 gene in NSCLC cell lines and tumours. RT–PCR amplification of cDNA from LKB1 wt (H441) and LKB1 mutant
(A549, H1395, and H23) cell lines display the full length LKB1 mRNA (1.4kbp) while the LKB1 mutant cell line, H2126 with a deletion of exons 4–6
expresses a shorter mRNA (1.0kbp) (A). HPLC tracings of SURVEYOR-WAVE mutation analysis of NSCLC cell lines A549, H1395, or H23 (continuous
line), and H441 (dashed line). Time in minutes is shown on the X-axis, voltage in mV on the Y-axis (B). A549 and H1395 show novel peaks (*) in the
amplicon covering exons 1–5 (ex1–5) corresponding to 109C4T, Q37X and 165_169delG, frameshift and truncation (FS truncation) mutations. The
analysis from H23 demonstrates novel peaks in the amplicon covering exons 5–9 (ex5–9) corresponding to 996G4T, W332X mutation. LKB1 wild-type
cDNA (H441) was added to PCR products 1:1, denatured by heating and slowly renaturated to generate heteroduplexes since A549, H1395, and H23
have previously reported to be homozygous for the LKB1 mutations. SURVEYOR-WAVE mutation analyses of NSCLC tumours (C). AD367 and AD368
tumours showed novel peaks in the ex1–5 amplicon corresponding to 475C4T, Q159X, and 142_143delA, FS, truncation mutations. AD362 tumour had
novel peaks in ex5–9 amplicon corresponding to deletion of exon 6. Mutant sequences for AD367 and AD368 are displayed from sequences using the
forward primer while mutation of the AD362 is showed with reverse primer.
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scollected from patients in the United States, whereas only nine
mutations (5% of specimens) were detected in the Korean cohort
(P¼0.001) (Table 1). The LKB1 mutation rate tended to be higher
in adenocarcinomas (13%) compared with squamous cell
carcinomas (5%) (P¼0.067). Differences in histological subgroups
were relatively modest in the US cohort with mutations in 18 out of
94 (19%) adenocarcinomas vs 5 out of 38 (13%) in squamous cell
cancers (P¼0.461). This is in contrast to the findings in the Asian
patients where all of the LKB1 mutations were detected in
adenocarcinomas (9 out of 113 (8%)) and none were detected in
squamous cell cancers (0 out of 54 (0%); P¼0.032). Nevertheless,
the higher rate of LKB1 mutation in adenocarcinomas compared
with squamous cell carcinomas retains the same level of statistical
significance (stratified P¼0.064) after adjusting for fluctuation
between ethnic groups. The US cohort also included nine
specimens from adenosquamous carcinomas and two out of nine
(22%) had LKB1 mutations, which is similar to the frequency in
adenocarcinomas in this population (Table 1). There was no
association between LKB1 mutations and the clinical stage of the
NSCLC patients. Kaplan–Meier survival curves of stages I and II
NSCLC patients showed a tendency for shorter survival in patients
with LKB1 mutant tumours but this, however, did not reach
statistical significance (P¼0.17) (Figure 2). No differences in
survival were observed in patients who harboured both LKB1 and
KRAS mutations compared with those with KRAS or LKB1 alone but
the total number of patients with both mutations who had stages I
or II NSCLC was small (n¼9; data not shown). We detected an
association of LKB1 mutations with a smoking history (P¼0.007)
and only two mutations were detected in tumours from 72 NSCLC
patients who were either never or light (p10 pack years) former
smokers (Table 1). After adjusting for ethnic group, the higher rate
of LKB1 mutation among patients with a smoking history is
borderline significant (stratified P¼0.067). The reduction in
statistical significance is likely owing to the loss of power associated
with the overall rarity of LKB1 mutations among never or light
former smokers. For these analyses we combined both never
smokers and light (p10 pack years) smokers as the frequency of
mutations in other oncogenes such as EGFR is similar in these two
patient groups (Pham et al, 2006). There were no correlations
between LKB1 mutations and gender or age of a patient.
Association of LKB1 mutations with K-Ras, B-Raf, and
EGFR mutations in NSCLC
Previous reports have suggested that in NSCLC cell lines, LKB1
mutations often occur concurrently with KRAS or BRAF mutations
Table 1 Frequency of LKB1 mutations in NSCLC tumours and their
association with clinicopathological characteristics
LKB1 mutation
+   P-value*
All tumours 34 (11%) 276 (89%)
Age, median 61.2 62.2
Ethnicity
Caucasian cohort 25 (17%) 118 (83%) 0.001
Asian cohort 9 (5%) 158 (95%)
Gender
Male 20 (11%) 167 (89%) NS
Female 14 (12%) 107 (88%)
Smoking
Never (o10py) 2 (3%) 70 (97%) 0.007
Smoker (410py) 26 (14%) 161 (86%)
Tumour stage
I 19 (10%) 169 (90%) NS
II 8 (14%) 51 (86%)
III 5 (11%) 42 (89%)
IV 1 (12%) 7 (88%)
Histology
Adenocarcinoma 27 (13%) 180 (87%) 0.047
Squamous carcinoma 5 (5%) 87 (95%)
Adenosquamous 2 (22%) 7 (78%)
*Fisher’s exact test, NS¼not statistically significant (P40.05).
Table 2 The specific LKB1 mutations in NSCLC tumours
Mutation
type
No.
(%) Mutation
Amino
acid
change Exon Histology
Missense 7 (21)
a526G4T D176Y 4 Ad
a580G4T D194Y 4 Ad
580G4T D194Y 4 Sq
829G4T D277Y 6 AdSq
a842C4T P281L 6 Ad
a842C4T P281L 6 Ad
1276C4T R426W 9 Ad
Nonsense 2 (6) 206C4A S69X 1 Ad
475C4T Q159X 4 Ad
Deletion/
insertion
25 (74)
a75_76del2&insT FS, truncates 1 Ad
120_130del11 FS, truncates 1 Ad
125_127insGG FS, truncates 1 Ad
128_129delC FS, truncates 1 Ad
142_143delA FS, truncates 1 Ad
180delC FS, truncates 1 Ad
209delA FS, truncates 1 Ad
227_228delC FS, truncates 1 Ad
47_651del604 FS, truncates 1-5 Sq
153_536del384 FS, truncates 1-4 AdSq
aexon 2-3del Truncates 2-3 Sq
aexon 2-3del Truncates 2-3 Ad
exon 2-3del Truncates 2-3 Ad
exon 2-4del FS, truncates 2-4 Sq
464_465del2insTTTGCT FS, truncates 3-4 Sq
562_563delG FS, truncates 4 Ad
aexon 4del FS, truncates 4 Ad
exon 4del FS, truncates 4 Ad
exon 4del FS, truncates 4 Ad
exon 4del FS, truncates 4 Ad
610_623del14 FS, truncates 5 Ad
a837_844delC FS, truncates 6 Ad
837_844insC FS, truncates 6 Ad
exon 6del FS, truncates 6 Ad
1038_1040insG FS, truncates 8 Ad
Ad¼Adenocarcinoma; AdSq¼Adenosquamous carcinoma; Sq¼Squamous cell
carcinoma; .
aThese mutations were detected in Korean NSCLC patients.
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Figure 2 Kaplan–Meyer survival curves of stage I and II NSCLC patients
with LKB1 wildtype (red line, n¼198) vs LKB1 mutant (blue line, n¼23)
tumours.
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s(Sanchez-Cespedes et al, 2002; Carretero et al, 2004). Furthermore,
EGFR mutations are often mutually exclusive with KRAS mutations
in NSCLC (Kosaka et al, 2004; Marchetti et al, 2005). We used
combined data from previous papers (Sanchez-Cespedes et al,
2002; Carretero et al, 2004) and from Sanger institute’s databases
(Bamford et al, 2004) to analyse association of LKB1 mutations
with mutations of KRAS, BRAF, and EGFR. Analysis of LKB1
mutation harbouring NSCLC cell lines (A-427, A549, NCI-H1395,
NCI-H1666, NCI-H2122, NCI-H2126, NCI-H23, and NCI-H460)
showed that five of the cell lines (63%) had concurrent LKB1 and
KRAS mutations, two (25%) had concurrent LKB1 and BRAF
mutations, and only one (13%) had neither KRAS nor BRAF
mutations. None of these cell lines had EGFR mutations.
As our findings in NSCLC cell lines suggested concurrency of
KRAS or BRAF and mutual exclusiveness of EGFR mutations with
LKB1 mutations, we analysed the mutational status of these genes
in our primary NSCLC tumour specimens. KRAS mutations were
detected in 49 (16% in the whole tumour set, 25% in Caucasian and
8% in Asian specimens) tumour specimens with 10 (20% of KRAS
mutants) of these occurring concurrently with an LKB1 mutation
(P¼0.042) (Table 3). Four BRAF mutations (1%) were found in
the tumour set (G465V, N581S, L596R, and T599I) and one of these
(N581S) occurred concurrently with LKB1 mutation (P¼0.373).
Seventy tumours (23% in the whole tumour set, 9% in Caucasian,
34% in Asian specimens) had EGFR kinase domain mutations with
only one of them occurring concurrently with an LKB1 mutation
(P¼0.002). The tumour with a concurrent EGFR and LKB1
mutation had a missense mutation of LKB1 outside the kinase
domain (R426W). No germ line DNA was available from this
patient. However, a recent report has suggested that R426W is in
fact a rare polymorphism of the gene (Onozato et al, 2007). Taken
together our findings suggest that unlike KRAS, mutations in EGFR
and LKB1 are mutually exclusive in NSCLC.
Previous reports (Sanchez-Cespedes et al, 2002; Carretero et al,
2004) and Cancer Genome Project by Sanger Institute (Bamford
et al, 2004) have extensively characterised LKB1 mutations in
NSCLC cell lines with KRAS and BRAF mutations, but LKB1 status
of EGFR mutant NSCLC cell lines has not been extensively
analysed. Therefore, we analysed the LKB1 genotype of NSCLC cell
lines with known EGFR or ERBB2 mutations. Twelve EGFR mutant
and one ERBB2 mutant cell lines were analysed for LKB1 genotype.
No LKB1 mutations were detected in these cell lines (Table 4).
DISCUSSION
The present study characterised LKB1 mutation frequency in
NSCLC using one of the largest tumour sets to date (n¼310). Our
study analysed tumours from different histologies and of both a US
and Korean origin to determine potential histological and ethnic
variation in LKB1 mutational frequency. The large size of our
study enabled us to study associations of LKB1 mutations with
clinocopathological factors, which have been incompletely char-
acterised in previous studies (Sanchez-Cespedes et al, 2002;
Carretero et al, 2004; Fernandez et al, 2004; Matsumoto et al,
2007; Onozato et al, 2007). In addition, we used a modification of a
sensitive mutation screening technique that we have previously
developed to facilitate the rapid detection of LKB1 mutations
(Janne et al, 2006).
Findings from our study confirm the high frequency of LKB1
mutations in NSCLC (11%), which in contrast, are rare (0–4%) in
other common solid malignancies (Avizienyte et al, 1998, 1999).
The reason behind these observations is presently unknown but
might reflect the differences in carcinogen exposure in the lungs
compared with other tissues. In support of this hypothesis, we find
that LKB1 mutations are significantly (P¼0.007) more common in
smokers than in never or light (p10 pack years) cigarette smokers
(Table 1). Male PJS patients (age X50 years) have an increased risk
of developing lung cancer compared with the general population
but the relationship of smoking and the increased risk of lung
cancer in PJS is unknown (Hearle et al, 2006). Interestingly, the
LKB1 mutation spectrum found in the current study is very similar
to those previously published for PJS (deletions 34%, insertions
15%, splice site mutations 14%, missense mutations 21%, and
nonsense mutations 12%) (Launonen, 2005) and, as in PJS, no
clear mutational hotspots were detected.
Our study also demonstrated that the LKB1 mutation frequency
was significantly higher in cancers derived from a US population
compared with those found in Korean patients (17 vs 5%;
P¼0.001). These differences also track with cigarette smoking,
as the number of never/light former smokers was much higher in
the Korean cohort compared with the US cohort of patients (38 vs
13%). Similarly, a recent study of 100 Japanese NSCLCs found that
only 3% contained an LKB1 mutation (Onozato et al, 2007). These
findings are in contrast to EGFR mutations, which are more
frequently detected in tumours from never/light cigarette smokers
and from Asian patients (Janne and Johnson, 2006). Our studies
further highlight ethnic and environmental differences in the
origins of NSCLC.
Given the differences in LKB1 mutation frequencies in smokers
vs never/light smokers and in the US compared with Korean
patients, we further determined whether these were also associated
with other oncogene mutations known to vary in these subgroups
of patients. Consistent with prior studies we found a significant
association with concurrent KRAS mutations, which are common
in smokers (Ahrendt et al, 2001), in one out of three of NSCLC
with LKB1 mutations (Table 3). In contrast, there was a significant
inverse relationship of LKB1 mutations with EGFR mutations in
both NSCLC tumours and cell lines, which has not previously been
Table 4 LKB1 genotypes of NSCLC cell lines with EGFR or ERBB2
mutations
Cell line EGFR genotype HER2 genotype LKB1 genotype
H1650 E746_A750del Wt Wt
H1781 Wt G776V, Cins Wt
H1975 L858R, T790M Wt Wt
H3255 L858R Wt Wt
H3255GR L858R, T790M Wt Wt
H820 L747_L751del, T790M Wt Wt
HCC2279 E746_A750del Wt Wt
HCC2935 E746_T751del, S752I Wt Wt
HCC4006 L747_E749del, A750P Wt Wt
HCC827 E746_A750del Wt Wt
Ma-1 E746_A750del Wt Wt
Ma-70 L858R Wt Wt
PC-9 E746_A750del Wt Wt
Wt¼wild type.
Table 3 Association of LKB1 mutations with KRAS, BRAF, and EGFR
mutations in NSCLC tumours
LKB1 mutation
+   P-value*
EGFR mutation + 1 69 0.002
  33 207
K-Ras mutation + 10 39 0.042
  24 237
B-Raf mutation + 1 3 0.373
  33 273
*Fisher’s exact test.
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biological role of LKB1 in lung cancer. It is possible that in EGFR
mutant lung cancers there is already maximal activation of the
PI3K/Akt/mTOR signalling pathway and thus an LKB1 mutation
may not be required to further potentiate this signalling pathway.
In contrast in KRAS mutant cancers, a concurrent LKB1 mutation
may be required to enhance mTOR activation. Mice with
concurrent KRAS mutations and LKB1 inactivation have more
aggressive tumours and a shorter survival than those with only
KRAS mutant cancers (Ji et al, 2007). In our study, we were not
able to detect a significant survival difference for patients whose
tumours contained LKB1 mutations alone or concurrently with
KRAS mutations (data not shown) likely because of the limited
number of tumour specimens. Additional studies are needed to
clarify the prognostic impact of LKB1 mutations in humans
with NSCLC. In the present study B2 out of 3 of LKB1 mutant
tumours were KRAS wild type (Table 3). One possibility is that such
tumours contain a concurrent mutation in another oncogene that
activates the same signalling pathway as KRAS. For this reason, we
examined our tumours for BRAF mutations, which are found in 1–
2% of NSCLC (Naoki et al, 2002). We detected a concurrent LKB1
mutation in one of the four BRAF mutant tumours (Table 3). This
tumour was wild type for KRAS (data not shown). In addition, some
of the BRAF mutant NSCLC cell lines (NCI-H1395, G469A; NCI-
H1666, G466V) also contain a concurrent LKB1 mutation (Sanchez-
Cespedes et al,2 0 0 2 ;B a m f o r det al, 2004; Carretero et al, 2004).
Future studies will help further clarify whether LKB1 mutations
occur concurrently with other genomic alterations in NSCLC and
the impact of this on patient outcome.
Our study employed a mutation scanning technology to screen
for LKB1 mutations at the cDNA level (Janne et al, 2006). This was
advantageous as the entire coding region of LKB1 could be rapidly
screened for a mutation using just two overlapping cDNA
fragments. LKB1 is a challenging gene to analyse at the genomic
DNA level because of its high guanine–cytosine content. In
addition, as many of the LKB1 mutations are small deletions
(Table 2) or involve deletions of entire exons, these would be
missed using exon-specific genome sequencing methods. Our
method, however, does have limitations as it would miss deletions
at the site of PCR primers, whole gene deletions, or deletions
within the promoter region all of which have been infrequently
detected in PJS (Volikos et al, 2006). Thus our studies may
underestimate the true LKB1 mutation frequency in NSCLC. In
addition, our method is limited to the analysis of fresh tumour
specimens, which are available only from the minority of NSCLC
patients. Furthermore, as techniques isolating mRNA from
formalin-fixed paraffin-embedded tumour specimens continue to
improve, this rapid mutation scanning technique can be used to
analyse broader populations of tumours from NSCLC patients.
Future studies may need to employ a combination of LKB1
mutation detection methodologies including the current method,
MLPA and direct sequencing.
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